These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31064024)

  • 1. [Urethral sarcoma 14 years after brachytherapy of the prostate gland].
    Comploj E; Hanspeter E; Trenti E; Palermo S; Pycha A
    Aktuelle Urol; 2019 Jul; 50(3):298-300. PubMed ID: 31064024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dosimetry of prostate brachytherapy-induced urethral strictures.
    Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.
    Kaufman DS; Zietman AL; Dahl DM; Harisinghani MG; Wu CL
    N Engl J Med; 2011 Feb; 364(7):667-75. PubMed ID: 21323545
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer.
    Domínguez A; Piulats JM; Suárez JF; Condom E; Castells M; Camps N; García Del Muro FX; Franco E
    Acta Oncol; 2013 Aug; 52(6):1215-6. PubMed ID: 23095143
    [No Abstract]   [Full Text] [Related]  

  • 5. Postradiation prostatic sarcoma: de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma?
    Canfield SE; Gans TH; Unger P; Hall SJ
    Tech Urol; 2001 Dec; 7(4):294-5. PubMed ID: 11763492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
    Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
    Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-induced prostatic sarcoma: a case report.
    Scully JM; Uno JM; McIntyre M; Mosely S
    J Urol; 1990 Sep; 144(3):746-8. PubMed ID: 2388344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
    Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
    Sekiguchi A; Tsumura H; Kawakami S; Satoh T; Iwamura M; Ishiyama H
    Int J Urol; 2019 Sep; 26(9):938-939. PubMed ID: 31256422
    [No Abstract]   [Full Text] [Related]  

  • 14. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.
    Cunha JA; Pouliot J; Weinberg V; Wang-Chesebro A; Roach M; Hsu IC
    Brachytherapy; 2012; 11(5):348-53. PubMed ID: 21937284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of edema on urethral dose following palladium-103 prostate brachytherapy.
    Gejerman G; Mullokandov E; Saini AJ; Lanteri V; Scheuch J; Vitenson J; Rosen J; Garden R; Sawczuk I
    Med Dosim; 2002; 27(3):221-5. PubMed ID: 12374379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer.
    Díez P; Mullassery V; Dankulchai P; Ostler P; Hughes R; Alonzi R; Lowe G; Hoskin PJ
    Radiother Oncol; 2014 Dec; 113(3):410-3. PubMed ID: 25544648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.